Transcode Therapeutics, Inc.

General Information

TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Our drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively.

(Note: TransCode Therapeutics priced its IPO on July 8, 2021, in line with the terms in its amended prospectus: 6.25 million shares at $4 to raise $25 million. On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 million, according to an S-1/A filing. The estimated IPO proceeds are the same – $25.2 million – but the market valuation, based on mid-point pricing, was cut by 37 percent to about $48 million on the current terms, down from $76.41 million previously.)

Employees: 6
Founded: 2016
Contact Information
Address 6 Liberty Square, #2382 Boston, MA 02109
Phone Number (857) 837-3099
Web Address
View Prospectus: Transcode Therapeutics, Inc.
Financial Information
Market Cap $47.88mil
Revenues $0 mil (last 12 months)
Net Income $-2.34 mil (last 12 months)
IPO Profile
Symbol RNAZ
Exchange NASDAQ
Shares (millions): 6.3
Price range $4.00 - $4.00
Est. $ Volume $25.0 mil
Manager / Joint Managers ThinkEquity
CO-Managers -
Expected To Trade: 7/9/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change